ArticleFrontiers in oncology2025

European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study.

Cristina Saura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.